JPSIM Journal of Pakistan Society of Internal Medicine J Pak Soc Intern Med 2709-8729 2710-0804 Pakistan Society of Internal Medicine 10.70302/jpsim.v6i4.2569 jpsim.v6i4.2569 Original Research Polyethylene Glycol in the Treatment of Hepatic Encephalopathy in patients with Liver Cirrhosis Khan Kamran Amir kkhan@nwgh.pk * Qureshi Sameed Ullah Khan Zuhra Naheed Northwest General Hospital and Research Center, Peshawar Pakistan kidney and liver institute, Lahore *Correspondence: Kamran Amir Khan (kkhan@nwgh.pk) 21 11 2025 2025 6 4 373 375 11 04 2024 14 06 2025 10 10 2025 Copyright © 2025 The Author(s) 2025 The Author(s) https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective

This study aims to determine the effectiveness and safety of polyethylene glycol (PEG) in patients with hepatic encephalopathy.

 Methodology

This cross-sectional study was conducted at Northwest General Hospital and Research Centre, Peshawar, Pakistan. All patients participated in this study were diagnosed with hepatic encephalopathy from January 2019 to August 2021. All patients were given 3 sachets of polyethylene glycol daily. Recovery days, length of hospital stay, and recurrent episodes were assessed.

 Results

A total of 75 patients with different hepatic diseases admitted to the hospital due to hepatic encephalopathy were given 3 sachets of polyethylene glycol daily. On average, 2.81 days for recovery and 5 days of hospital stay were required. The mean number of recurrent hepatic encephalopathy episodes was 0.52.

 Conclusion

Polyethylene glycol is considered effective and safe in patients with hepatic encephalopathy, with short recovery days, hospital stay, and few recurrent episodes.

 Keywords Hepatic encephalopathy polyethylene glycol liver cirrhosis. Ethics Statement

Ethics committee: Ethics Committee, Northwest General Hospital and Research Centre, Peshawar, Pakistan. Approval number: NWGH/EC/14, dated October 04, 2021.

 References Rudler M, Weiss N, Bouzbib C, Thabut D. Diagnosis and management of hepatic encephalopathy. Clin Liver Dis. 2021;25(2):393-417. Weiss N, Jalan R, Thabut D. Understanding hepatic encephalopathy. Inten Care Med. 2018;44:231-4. Butterworth RF, Layrargues GP. Hepatic Encephalopathy: Pathophysiology and Treatment. Springer Science & Business Media; 2012; ISBN: 1461245060, 9781461245063 Tsoris A, Marlar CA. Use of the Child Pugh score in liver disease. StatPearls Publishing, Treasure Island (FL). 2023;PMID: 31194448. Salerno F, Merli M, Cazzaniga M, Valeriano V, Rossi P, Lovaria A, et al. MELD score is better than Child–Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol. 2002;36(4):494-500. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol. 2022;77(3):807-24. Fallahzadeh MA, Rahimi RS. Hepatic Encephalopathy: Current and Emerging Treatment Modalities. Clin Gastroenterol Hepatol. 2022;20(8):S9-19. Jalan R, Rose CF. Heretical thoughts into hepatic encephalopathy. J Hepatol. 2022; 77(2):539-48. Li M, Zhang Z, Chen Q, Zhou X, Shui D, Huang J. Comparative effectiveness and safety of polyethylene glycol electrolyte solution versus lactulose for treatment of hepatic encephalopathy: a systematic review and meta-analysis. J Clin Gastroenterol. 2022;56(1):41. Sawhney R, Jalan R. The gut is a key target of therapy in hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2015;12(1):7-8. Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350-electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Int Med. 2014;174(11):1727-33. Shehata HH, Elfert AA, Abdin AA, Soliman SM, Elkhouly RA, Hawash NI, Soliman HH. Randomized controlled trial of polyethylene glycol versus lactulose for the treatment of overt hepatic encephalopathy. Eu J Gastroenterol Hepatol. 2018;30(12):1476-81. Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, et al. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. J Hepatol. 2020;73(6):1526-47. Raja WJ, Sebastian B, Mathai SK. To compare the effect of polyethylene glycol vs. lactulose in the treatment of overt hepatic encephalopathy. Hepatol Gastroint Dis. 2019;5:166. Hoilat GJ, Ayas MF, Hoilat JN, Abu-Zaid A, Durer C, Durer S, et al. Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2021;8(1):e000648.